Abstract
A methodology for producing a pediatric medicinal formulation consisting of granules containing an extract of the milk-white iris (MWIE) was developed. Accessory substances were selected on the basis of the high hygroscopicity and low solubulity of the extract; the optimum conditions for granule production were selected (structural granule formation in a semifluidized bed process). The yield of granules using this methodology was 97.5%. Granules containing MWIE were not toxic (LD50 = 5.0–7.7 g/kg) and positive results were obtained on assessment of immunotropic activity. The Manufacturer’s Pharmacopeia Article and laboratory guidelines were developed for the pediatric MWIE-containing medicinal granules.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
